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Volcano plot of DNA methylation in 
prostate cancer versus adjacent benign 
tissue. Differentially methylated CpGs are 
labeled in green or red. The 27 red-
labeled CpG sites had a mean 
methylation difference of at least 40% 
between cancer and benign tissue; all 
were hypermethylated. 
 






Methylation of DNA is a well-known epigenetic mechanism for the control of gene 
expression.  Methylation commonly occurs at CpG sites, or regions of DNA where a cytosine 
nucleotide occurs next to a guanine nucleotide. These sites tend to cluster into islands and are often 
found in gene promoter regions. CpG islands are typically unmethylated, thus allowing for 
uninhibited transcription of the gene, while hypermethylation of these regions can lead to 
transcriptional silencing. Losses and gains of DNA methylation have been associated with various 
cancers, including prostate cancer.  
While previous research has investigated methylation in relation to prostate cancer, the majority of 
studies have examined methylation in only a select number of genes. To address this caveat, Drs. 
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Milan Geybels, Janet Stanford, and colleagues (Public Health Sciences Division) evaluated DNA 
methylation changes epigenome-wide in paired prostate cancer and adjacent benign tissue samples. 
This work, recently published in The Prostate, aimed to discover novel differences in methylation 
between cancerous and benign tissue samples and determine if previous findings from smaller 
studies would replicate in their larger study. 
Paired samples came from 20 radical prostatectomy patients, 18 European Americans and 2 African 
Americans. The authors conducted epigenome-wide profiling and found over 2,000 CpG sites with 
differential DNA methylation; the majority of these CpGs were hypermethylated in cancer versus 
benign tissue. The average hypermethylation difference was 26%.  
For verification of their results, the authors examined the 27 top-ranked differentially methylated CpG 
sites in 46 participants from the prostate cancer dataset in The Cancer Genome Atlas (TCGA). 
Confirming their initial findings, all 27 CpG sites were significantly hypermethylated in the cancerous 
tissue using TCGA. Next, the authors evaluated gene expression levels of these hypermethylated 
top-ranked regions. Of the 18 genes that had transcript data available, three genes (SCGB3A1, 
HIF3A, and AOX1) had reduced messenger RNA (mRNA) expression in cancer versus benign 
tissue. 
Dr. Geybels describes the impact of this work, "we identified specific DNA methylation changes in 
prostate tumor tissue compared to non-cancer prostate tissue. These DNA methylation changes 
were in specific genes, some of which have not been implicated in prostate cancer before," such as 
SCGB3A1, a gene suggested to function as a tumor-suppressor. Furthermore, "we also confirmed 
some previous findings of genes that are differentially methylated in prostate cancer, thereby 
providing further evidence for a role of these genes in prostate carcinogenesis. Our findings may 
therefore provide new insights into the development of prostate cancer."  
Additional Fred Hutch investigators contributing to this research were Shanshan Zhao, Chao-Jen 
Wong, and Dr. Michael Wu.  
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